This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kulkarni, A. A. Articles by Stoeber, K. Search for Related Content PubMed PubMed Citation Articles by Kulkarni, A. A. Articles by Stoeber, K.

DNA Replication Licensing Factors and Aurora Kinases are Linked to Aneuploidy and Clinical Outcome in Epithelial Ovarian Carcinoma

Authors' Affiliations: ¹ Department of Pathology, Royal Free and University College Medical School, ² Wolfson Institute for Biomedical Research, ³ Cancer Research UK and UCL Cancer Trials Centre, Department of Oncology, University College London, London, United Kingdom; and ⁴ Faculty of Science and Technology, Anglia Ruskin University, and ⁵ Centre for Applied Medical Statistics, Department of Public Health and Primary Care, Forvie Site, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom

Requests for reprints: Gareth H. Williams, Department of Pathology, Royal Free and University College Medical School, University College London, Rockefeller Building, University Street, London, WC1E 6JJ, United Kingdom. Phone: 44-207679-6304; Fax: 44-207388-4408; E-mail: gareth.williams{at}ucl.ac.uk.

Purpose: DNA replication licensing factors and Aurora kinases play critical roles in maintaining genomic integrity. We used multiparameter analyses of these cell cycle regulatory proteins to investigate their role in the progression of epithelial ovarian carcinoma (EOC).

Experimental Design: In a cohort of 143 patients, we linked the protein expression profiles of the proliferation marker Ki67, the replication licensing factors Mcm2 and geminin, and the Aurora A and B kinases to tumor DNA ploidy status and clinical outcome.

Results: Ki67, Mcm2, geminin, and Aurora A and B are significantly associated with tumor grade and ploidy status (P < 0.0001). Aurora A and its substrate H3S10ph are also significantly associated with Federation of International Obstetricians and Gynecologists tumor stage (P = 0.006 and P = 0.002, respectively). Aurora A and tumor ploidy status are predictive of disease-free survival in this cohort [hazard ratio (HR), 1.29; 95% confidence intervals (95% CI), 1.06-1.58, P = 0.01 and HR, 1.80 (1.05-3.08), P = 0.03, respectively], with Aurora A of particular prognostic importance in early stage disease [HR, 1.72 (1.19-2.48), P = 0.004 for disease-free survival and HR, 1.81 (1.14-2.87), P = 0.01 for overall survival].

Conclusions: Our data show that Ki67, Mcm2, geminin and Aurora A and B can be used as an adjunct to conventional prognostic indicators and as an aid to develop a tumor progression model for EOC. Dysregulation of Aurora A seems to be an early event in EOC with a key role in tumor progression. In view of present drug development programs for specific Aurora kinase inhibitors, our findings have important implications for the use of Aurora A as a biomarker and as a potential therapeutic target.